Logo image of KDMN

Kadmon Holdings Llc (KDMN) Stock Fundamental Analysis

NASDAQ:KDMN - Nasdaq -

9.5  +0.02 (+0.21%)

After market: 9.49 -0.01 (-0.11%)

Fundamental Rating

1

Taking everything into account, KDMN scores 1 out of 10 in our fundamental rating. KDMN was compared to 558 industry peers in the Biotechnology industry. KDMN may be in some trouble as it scores bad on both profitability and health. KDMN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KDMN has reported negative net income.
KDMN Yearly Net Income VS EBIT VS OCF VS FCFKDMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -35.84%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KDMN Yearly ROA, ROE, ROICKDMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -1K -2K -3K -4K

1.3 Margins

Industry RankSector Rank
OM -6354.85%
PM (TTM) -5955.81%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KDMN Yearly Profit, Operating, Gross MarginsKDMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -2K -4K -6K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for KDMN has been increased compared to 1 year ago.
Compared to 1 year ago, KDMN has a worse debt to assets ratio.
KDMN Yearly Shares OutstandingKDMN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 50M 100M 150M
KDMN Yearly Total Debt VS Total AssetsKDMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

KDMN has an Altman-Z score of 1.06. This is a bad value and indicates that KDMN is not financially healthy and even has some risk of bankruptcy.
KDMN has a Debt/Equity ratio of 6.96. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 6.96
Debt/FCF N/A
Altman-Z 1.06
ROIC/WACCN/A
WACCN/A
KDMN Yearly LT Debt VS Equity VS FCFKDMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M -100M 200M -200M

2.3 Liquidity

KDMN has a Current Ratio of 9.46. This indicates that KDMN is financially healthy and has no problem in meeting its short term obligations.
KDMN has a Quick Ratio of 9.46. This indicates that KDMN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 9.46
Quick Ratio 9.46
KDMN Yearly Current Assets VS Current LiabilitesKDMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.72% over the past year.
Looking at the last year, KDMN shows a very negative growth in Revenue. The Revenue has decreased by -84.20% in the last year.
KDMN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.33% yearly.
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
Revenue 1Y (TTM)-84.2%
Revenue growth 3Y-12.23%
Revenue growth 5Y-25.33%
Sales Q2Q%-56.22%

3.2 Future

The Earnings Per Share is expected to grow by 2.19% on average over the next years.
Based on estimates for the next years, KDMN will show a very strong growth in Revenue. The Revenue will grow by 153.65% on average per year.
EPS Next Y-11.43%
EPS Next 2Y0.07%
EPS Next 3Y12.98%
EPS Next 5Y2.19%
Revenue Next Year-3.81%
Revenue Next 2Y164.74%
Revenue Next 3Y157.81%
Revenue Next 5Y153.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KDMN Yearly Revenue VS EstimatesKDMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
KDMN Yearly EPS VS EstimatesKDMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KDMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KDMN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KDMN Price Earnings VS Forward Price EarningsKDMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -13.51
KDMN Per share dataKDMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

KDMN's earnings are expected to grow with 12.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.07%
EPS Next 3Y12.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KDMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Kadmon Holdings Llc

NASDAQ:KDMN (11/8/2021, 8:24:43 PM)

After market: 9.49 -0.01 (-0.11%)

9.5

+0.02 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.94%
Inst Owner Change0%
Ins Owners0.25%
Ins Owner Change0%
Market Cap1.63B
Analysts75
Price Target12.34 (29.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 875.04
P/FCF N/A
P/OCF N/A
P/B 48.83
P/tB N/A
EV/EBITDA -13.51
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.01
BVpS0.19
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -6354.85%
PM (TTM) -5955.81%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 6.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.46
Quick Ratio 9.46
Altman-Z 1.06
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
EPS Next Y-11.43%
EPS Next 2Y0.07%
EPS Next 3Y12.98%
EPS Next 5Y2.19%
Revenue 1Y (TTM)-84.2%
Revenue growth 3Y-12.23%
Revenue growth 5Y-25.33%
Sales Q2Q%-56.22%
Revenue Next Year-3.81%
Revenue Next 2Y164.74%
Revenue Next 3Y157.81%
Revenue Next 5Y153.65%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A